Galapagos increases share capital through warrant exercises
December 06 2013 - 12:49PM
Galapagos NV (Euronext:GLPG) announced today a capital
increase arising from employee and management warrant
exercises.
Since its inception in 1999, Galapagos has used
warrant plans to incentivize personnel and management and have them
share in the success of the company. Following warrant
exercises during the exercise period running from
20 November 2013 through 3 December 2013,
Galapagos issued 3,025 new ordinary shares on
6 December 2013 for a total capital increase (including
issuance premium) of €19,216.25.
Galapagos' Executive Committee has put a warrant
exercise program into place whereby Executive Committee members
have made a commitment to exercise a minimum number of warrants
during subsequent exercise periods, subject to certain
conditions. During this exercise period, one Executive
Committee member exercised warrants for a total of 2,500
warrants.
To date, Galapagos' total share capital amounts
to €161,171,635.86; the total number of securities conferring
voting rights is 29,794,046, which is also the total number of
voting rights (the "denominator"), and all securities conferring
voting rights and all voting rights are of the same category.
The total number of rights (warrants) to subscribe to not yet
issued securities conferring voting rights is 3,643,326, which
equals the total number of voting rights that may result from the
exercise of these warrants. Galapagos does not have any
convertible bonds or shares without voting rights outstanding.
About Galapagos
Galapagos (Euronext:GLPG) (OTC:GLPYY) is specialized in novel
modes-of-action, with a large pipeline comprising of six Phase 2
studies (three led by GSK), one Phase 1 study, five pre-clinical,
and 20 discovery small-molecule and antibody programs in cystic
fibrosis, inflammation, antibiotics, metabolic disease, and other
indications.
AbbVie and Galapagos signed an agreement in CF where they work
collaboratively to develop and commercialize oral drugs that
address two mutations in the CFTR gene, the G551D and F508del
mutation. In the field of inflammation, AbbVie and Galapagos
signed a worldwide license agreement whereby AbbVie will be
responsible for further development and commercialization of
GLPG0634 after Phase 2B. GLPG0634 is an orally-available,
selective inhibitor of JAK1 for the treatment of rheumatoid
arthritis and potentially other inflammatory diseases, currently in
Phase 2B studies in RA and about to enter Phase 2 studies in
Crohn's disease. Galapagos has another selective JAK1
inhibitor in Phase 2 in ulcerative colitis, psoriasis, and lupus,
GSK2586184 (formerly GLPG0778, in-licensed by GlaxoSmithKline in
2012). GLPG0974 is the first inhibitor of FFA2 to be
evaluated clinically for the treatment of IBD; this program is
currently in a Proof-of-Concept Phase 2 study. GLPG1205, a
first-in-class molecule that targets inflammatory disorders, has
completed Phase 1 studies.
The Galapagos Group, including fee-for-service companies
BioFocus, Argenta and Fidelta, has around 800 employees and
operates facilities in five countries, with global headquarters in
Mechelen, Belgium. Further information at: www.glpg.com
CONTACT Elizabeth Goodwin, Director Investor
Relations Tel: +31 6 2291 6240 ir@glpg.com
This release may contain forward-looking statements, including,
without limitation, statements containing the words "believes,"
"anticipates," "expects," "intends," "plans," "seeks," "estimates,"
"may," "will," "could," "stands to," and "continues," as well as
similar expressions. Such forward-looking statements may involve
known and unknown risks, uncertainties and other factors which
might cause the actual results, financial condition, performance or
achievements of Galapagos, or industry results, to be materially
different from any historic or future results, financial
conditions, performance or achievements expressed or implied by
such forward-looking statements. Given these uncertainties,
the reader is advised not to place any undue reliance on such
forward-looking statements. These forward-looking statements
speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any
such forward-looking statements in this document to reflect any
change in its expectations with regard thereto or any change in
events, conditions or circumstances on which any such statement is
based, unless required by law or regulation.
HUG#1748301
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Aristocrat (PK) (USOTC:ASCC)
Historical Stock Chart
From Jul 2023 to Jul 2024